| 042520 Stock | | | KRW 7,460 80.00 1.06% |
Director
Jun Park is Director of HansBiomed
| Age | 43 |
| Phone | 82 2 466 2266 |
| Web | https://www.hansbiomed.com |
HansBiomed Management Efficiency
The company has return on total asset
(ROA) of
(0.0946) % which means that it has lost $0.0946 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
13.6473 %, meaning that it generated $13.6473 on every $100 dollars invested by stockholders. HansBiomed's management efficiency ratios could be used to measure how well HansBiomed manages its routine affairs as well as how well it operates its assets and liabilities.
HansBiomed has accumulated 1.35
B in total debt with debt to equity ratio
(D/E) of 0.73, which is about average as compared to similar companies. HansBiomed has a current ratio of 1.81, which is within standard range for the sector. Debt can assist HansBiomed until it has trouble settling it off, either with new capital or with free cash flow. So, HansBiomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like HansBiomed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for HansBiomed to invest in growth at high rates of return. When we think about HansBiomed's use of debt, we should always consider it together with cash and equity.
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. HansBiomed Corporation was founded in 1993 and is based in Seoul, South Korea. HANS BIOMED is traded on Korean Securities Dealers Automated Quotations in South Korea. HansBiomed (042520) is traded on KOSDAQ in Korea and employs 15 people.
Management Performance
HansBiomed Leadership Team
Elected by the shareholders, the HansBiomed's board of directors comprises two types of representatives: HansBiomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HansBiomed. The board's role is to monitor HansBiomed's management team and ensure that shareholders' interests are well served. HansBiomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HansBiomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ho Hwang, Chief Executive Officer, Director | |
| Hong Yim, Director | |
| Guen Kim, Chief Officer | |
| Seok Oh, Chief Financial Officer, Assistant Managing Director | |
| Jin Kim, Director | |
| Jun Park, Director | |
| Geun Kim, Internal Auditor | |
| Seong Jeon, Director | |
| Won Gwon, Assistant Managing Director | |
| SeokBae Oh, Chief Director | |
| Yong Cho, Director | |
| Tae Kim, Director | |
| Gye Kang, Director | |
| Seong Park, Director | |
| WonGyun Kwon, MD Director | |
HansBiomed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HansBiomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Pair Trading with HansBiomed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HansBiomed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HansBiomed will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to HansBiomed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HansBiomed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HansBiomed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HansBiomed to buy it.
The correlation of HansBiomed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HansBiomed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HansBiomed moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HansBiomed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Other Information on Investing in HansBiomed Stock
HansBiomed financial ratios help investors to determine whether HansBiomed Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HansBiomed with respect to the benefits of owning HansBiomed security.